Daily Stock Analysis, AKBA, Akebia Therapeutics Inc, priceseries

Akebia Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
4.16
Close
4.32
High
4.40
Low
4.15
Previous Close
4.14
Daily Price Gain
0.18
YTD High
9.30
YTD High Date
Mar 12, 2019
YTD Low
3.50
YTD Low Date
Aug 6, 2019
YTD Price Change
-1.48
YTD Gain
-25.52%
52 Week High
10.45
52 Week High Date
Dec 13, 2018
52 Week Low
3.50
52 Week Low Date
Aug 6, 2019
52 Week Price Change
-4.82
52 Week Gain
-52.74%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Apr 24. 2017
9.31
May 10. 2017
11.97
12 Trading Days
28.54%
Link
LONG
May 12. 2017
12.69
May 26. 2017
13.51
10 Trading Days
6.49%
Link
LONG
Jun 19. 2017
14.61
Jun 28. 2017
15.51
7 Trading Days
6.15%
Link
LONG
Aug 11. 2017
14.29
Oct 9. 2017
18.90
40 Trading Days
32.24%
Link
LONG
May 11. 2018
9.83
May 25. 2018
10.33
10 Trading Days
5.13%
Link
LONG
Dec 10. 2018
8.89
Dec 13. 2018
9.67
3 Trading Days
8.77%
Link
LONG
Feb 4. 2019
5.80
Mar 6. 2019
7.24
21 Trading Days
24.76%
Link
LONG
Mar 11. 2019
7.34
Mar 29. 2019
8.18
14 Trading Days
11.40%
Link
LONG
Aug 8. 2019
4.17
Aug 21. 2019
4.44
9 Trading Days
6.43%
Link
LONG
Sep 9. 2019
4.28
Sep 16. 2019
4.79
5 Trading Days
11.93%
Link
Company Information
Stock Symbol
AKBA
Exchange
NasdaqGM
Company URL
http://www.akebia.com
Company Phone
617-871-2098
CEO
John P. Butler
Headquarters
Massachusetts
Business Address
245 FIRST STREET, SUITE 1100, CAMBRIDGE, MA 02142
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001517022
About

Akebia Therapeutics, Inc. is a biopharmaceutical company which engages in the development of novel proprietary therapeutics based on hypoxia-inducible factor biology and the commercialization of these products for patients with kidney disease. Its lead product candidate, AKB-6548, is in a Phase 2b clinical trial in patients with anemia secondary to chronic kidney disease who are not dependent on dialysis. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

Description

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product candidates that include AKB-6899 for the treatment of anemia; and AKB-5169, a preclinical compound for the treatment for inflammatory bowel disease. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, as well as with Mitsubishi Tanabe Pharma Corporation for the development and commercialization to vadadustat in Japan and other Asian countries. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.